Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.

We prospectively determined the measles-mumps-rubella (MMR) antibody status of 39 previously vaccinated children before and after administering protocol-directed chemotherapy for acute leukemia. At diagnosis the seropositivity rates for measles and mumps-specific immunoglobulin G were > or = 90%, while the seropositivity rate for rubella was 85%. After treatment, rates of seropositivity for measles antibody declined by 13% (90% of patients to 77%; P = .13); for mumps antibody, by 18% (97%-79%; P = .02); and for rubella antibody, by 21% (85%-64%; P = .03). These findings suggest that some survivors of acute leukemia during childhood have an increased susceptibility to MMR viruses and would benefit from posttreatment evaluation of their immune statuses and from possible revaccination.

[1]  D. Nalin,et al.  Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. , 1996, The Pediatric infectious disease journal.

[2]  C. Pui.  Acute leukemia in children , 1996, Current opinion in hematology.

[3]  P. Ljungman,et al.  Specific T and B cell immunity to measles after allogeneic and autologous bone marrow transplantation. , 1995, Bone marrow transplantation.

[4]  H. Grier,et al.  Treatment of Patients with Acute Myelogenous Leukemia: Review of Clinical Trials of the Past Decade , 1995, Journal of pediatric hematology/oncology.

[5]  V. Bonagura,et al.  Immunodeficiency in long-term survivors of acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster therapy. , 1995, The Journal of pediatrics.

[6]  W. Mason,et al.  Epidemic measles in the postvaccine era: evaluation of epidemiology, clinical presentation and complications during an urban outbreak , 1993, The Pediatric infectious disease journal.

[7]  T. Salmi,et al.  Recovery of blood B‐lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia , 1992, Cancer.

[8]  Robert T. Chen,et al.  Measles antibody: reevaluation of protective titers. , 1990, The Journal of infectious diseases.

[9]  P. Fine,et al.  Duration of live measles vaccine-induced immunity. , 1990, The Pediatric infectious disease journal.

[10]  F. Gigliotti,et al.  Measles and rubella antibody status in previously vaccinated children with cancer. , 1988, Medical and pediatric oncology.

[11]  O. Eden,et al.  Mortality and morbidity caused by measles in children with malignant disease attending four major treatment centres: a retrospective review. , 1987, British medical journal.

[12]  A. Craft,et al.  Measles in children who have malignant disease. , 1987, British medical journal.

[13]  J. Katz,et al.  Abnormal cellular and humoral immunity in childhood acute lymphoblastic leukemia in long-term remission. , 1987, The Western journal of medicine.

[14]  P. Albrecht,et al.  Role of virus strain in conventional and enhanced measles plaque neutralization test. , 1981, Journal of virological methods.

[15]  R. Webster,et al.  Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. , 1972, Blood.

[16]  J. Enders,et al.  Persistence of measles virus and depression of antibody formation in patients with giant-cell pneumonia after measles. , 1959, The New England journal of medicine.

[17]  J. Enders,et al.  Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash. , 1959, The New England journal of medicine.

[18]  C. Simpson,et al.  Pathology in leukemia complicated by fatal measles. , 1958, Pediatrics.